Ulcerative Colitis

Patients who are obese and underwent treatment with either bariatric surgery or weight-loss medications compared with persistently obese patients not exposed to either intervention are at lower risk for development of de-novo inflammatory bowel disease, according to study results.

Patients who underwent vagotomy were at greater risk for later development of inflammatory bowel disease, indicating the beneficial role of the vagal tone in IBD, according to research published in Alimentary Pharmacology & Therapeutics.

Real-world data from a multicenter study revealed that Stelara helped patients with ulcerative colitis achieve steroid-free remission, according to research published in Alimentary Pharmacology & Therapeutics.

The American Gastroenterological Association issued new guidance for the clinical management of patients with inflammatory bowel disease during the COVID-19 pandemic.

In this exclusive video series, Stephen B. Hanauer, MD, medical director of the Digestive Health Center at Northwestern University Feinberg School of Medicine, discusses the impact of COVID-19 on the world of gastroenterology. In this video, he told Healio Gastroenterology and Liver Disease about how it has affected patients with inflammatory bowel disease, as well as clinical trials.

A panel of serum antibodies and proteins helped identify patients who later received a diagnosis of Crohn’s disease within 5 years, according to research published in Gastroenterology.

For some patients with inflammatory bowel disease, treatments can be ineffective, and in patients where they do work, they do not always last.

Inflammatory bowel disease is a debilitating condition that takes a lifetime of treatment to control. Over the years, medical therapies for the disease have evolved greatly, but the approval of anti-tumor necrosis factor alpha therapy for the treatment of Crohn’s disease in 1998 was a turning point in IBD treatment management.

Patients diagnosed with inflammatory bowel disease in childhood attain a lower adult height than their peers without IBD, according to study results.

In this guest commentary, Anita Afzali, MD, medical director of the Inflammatory Bowel Disease Center at The Ohio State University Wexner Medical Center, discusses the highlights from the recent IBD Horizons conference held Feb. 29, in Columbus, Ohio.